Anvisa approves the first biosimilar monoclonal antibody based on comparability in brazil
Arq. gastroenterol
; 53(2): 60-61, April.-June 2016.
Article
in En
| LILACS
| ID: lil-783814
Responsible library:
BR1.1
Key words
Full text:
1
Index:
LILACS
Main subject:
Gastrointestinal Agents
/
Drug Approval
/
Biosimilar Pharmaceuticals
/
Infliximab
/
Antibodies, Monoclonal
Limits:
Humans
Country/Region as subject:
America do sul
/
Brasil
Language:
En
Journal:
Arq. gastroenterol
Journal subject:
GASTROENTEROLOGIA
Year:
2016
Type:
Article